Simcere takes a stake in Boda Pharma

China-based Simcere Pharmaceutical Group announced that it will acquire a 51 percent stake in Boda Pharmaceutical. Simcere produces a neuroprotective stroke management medication, and Boda manufactures the only other injectable edaravone products in China. By taking a stake in Boda, Simcere will own the entire injectable edaravone market in the country.

- check out Simcere's release for more

Suggested Articles

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.

After culling a $2.6 billion biobucks pact last year, Bristol Myers Squibb is making a second and final cut to its pact with I-O biotech Jounce.

With its $400 million Fund XII, Atlas Venture became the latest VC shop to close a major fund since the WHO officially declared COVID-19 a pandemic.